On April 13, 2023, Biostage, Inc. closed the transaction. The company received $2.405802 million in its final tranche for the gross proceeds of $6.005802 million. The transaction included participation from 14 investors.
Harvard Apparatus Regenerative Technology Inc.
Equities
HRGN
US09074M2026
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.921 USD | -0.31% |
|
+11.49% | -41.46% |
1st Jan change | Capi. | |
---|---|---|
-41.46% | 4.18Cr | |
+4.18% | 21TCr | |
+8.00% | 19TCr | |
+31.86% | 16TCr | |
+33.21% | 11TCr | |
+2.28% | 6.43TCr | |
+21.14% | 5.57TCr | |
+0.11% | 4.84TCr | |
-6.76% | 3.78TCr | |
+0.78% | 3.56TCr |
- Stock Market
- Equities
- HRGN Stock
- News Harvard Apparatus Regenerative Technology Inc.
- Biostage, Inc. announced that it has received $6.005802 million in funding